RecruitingPhase 1NCT06805994

Administering NMT to Reestablish Infant Nasal Microbiome Diversity Following Intranasal Mupirocin Treatment

Parent-to-Child Nasal Microbiota Transplant to Reestablish Nasal Microbiome Diversity After Intranasal Mupirocin Treatment of Children With Staphylococcus Aureus Nasal Colonization

Sponsor

Johns Hopkins University

Enrollment

175 participants

Start Date

Aug 27, 2025

Study Type

INTERVENTIONAL

Conditions

Microbial Colonization Staphylococcal Aureus Infection Pediatric Infection S. Aureus Colonization Microbial Transplant

Summary

This protocol aims to evaluate how NMT affects pediatric nasal microbiome diversity following intranasal mupirocin treatment

Eligibility

Min Age: 0 YearsMax Age: 60 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a biological treatment called Nasal Microbiota Transplant (NMT) and a biological treatment called Placebo for people with microbial colonization, microbial transplant, and other related conditions. The study is currently recruiting participants at 1 location. People eligible for this study include aged 0 Years to 60 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.